吉西他滨联合奥沙利铂治疗淋巴瘤患者的疗效及安全性评价  

Safety and Efficacy Evaluation of Gemcitabine Combined with Oxaliplatin for the Treatment of Patients with Lymphoma

作　　者：陈碧玲[1] 赵哲[1] 覃仕海 刘莉[1] 谭庆玲[1] 

机构地区：[1]湖北民族学院附属民大医院内分泌血液核医学科,湖北445000

出　　处：《中国实验血液学杂志》2015年第2期445-449,共5页Journal of Experimental Hematology

摘　　要：目的:探析吉西他滨联合奥沙利铂(GEMOX)方案治疗淋巴瘤近期疗效及安全性,为今后合理选择化疗方案提供参考和借鉴。方法:收集本院内分泌血液科2010年1月-2013年1月期间经GEMOX方案化疗的64例复发性、难治性非霍奇金淋巴瘤(NHL)患者的临床资料,分析近期疗效、毒副作用及发生率以及近期生存情况。结果:B症状改善率86.36%;38例血浆LDH升高者化疗结束LDH水平均明显降低。化疗结束后64例患者客观有效率(ORR)为68.75%,临床有效率(CBR)为87.50%,不同IPI评分患者DRR和CBR比较差异有显著统计学意义(P<0.05)。不良反应主要为血液毒性反应及消化道反应,但均较轻微,停药或者对症处理后减轻或者消失。中位PFS时间为10.5个月。结论:吉西他滨联合奥沙利铂方案对于复发性、难治性淋巴瘤疗效显著,毒副作用低,可作为二线化疗方案应用于临床。Objective：To investigate the short-term efficacy and safety of GEMOX regimen for the treatment of lymphoma, so as to provide the reference for further rational selection of chemotherapy. Methods.A total of 61 patients with relapse and refractory non-Hodgkin＇s lymphoma （NHL） treated with chanotherapy of GEMOX regimen from 2010 Jannary -2013 year were selected, and their clinical data were collected, and the short-term efficacy, toxic effects and short-term survival were analyzed. Results：The improved rate of B symptom was 86.36% ; the LDH level in 38 cases with high LDH level after chemotherapy all obviously decreased; the ORR and CBR in 64 patients after treatment were 68.75% and 87.50% respectively; the comparison of ORR and CBR between patients with different IPI score showed significantly statistical difference （P 〈 0.05 ）. The adverse reactions mainly observed in blood and digestive tract, but were mild; adverse reactions were reduced or disappeared after stoping drugs or symptomatic treatment. The median progression-free survival time of patients was 10.5 months. Conclusion： Gemcitabine combined with oxaliplatin for treatment of relapse-refractory lymphoma shows singnificant efficacy and low toxicity, this regimen can be used as a second-line chemotherav in clinic.

关 键 词：吉西他滨 奥沙利铂 非霍奇金淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤]